Sandra Nestler-Parr, PhD, MPhil, MSc, is Senior Vice President, Value and Patient Access at BioCryst Pharmaceuticals, where she leads the integrated market access, health economics and outcomes research, and patient engagement function. She is responsible for developing and executing evidence-driven strategies that support patient-centered development and secure sustainable access to innovative therapies for rare diseases worldwide.

Sandra brings more than 25 years of experience across academia, the biopharmaceutical industry, consulting, and the nonprofit sector. She began her career in academic medical research before transitioning to industry, where she has held a series of senior international leadership positions. Her expertise includes outcomes research, value demonstration, real-world evidence generation, health technology assessment strategy, market access, health policy, and patient engagement.

Early in her career, Sandra developed a particular interest in rare diseases and addressing areas of significant unmet need where healthcare innovation can transform patients’ lives, but systematic and rigorous evidence generation can be challenging.

A strong advocate for incorporating the perspectives of patients and underrepresented stakeholders into healthcare decision-making, Sandra has championed patient-centered, multistakeholder approaches throughout her career. She has served for 12 years on the Board of Trustees of Alpha-1 UK, a rare disease patient advocacy organization, and as a pro bono external advisor to EURORDIS on several major multistakeholder projects. She has also contributed to European and UK research and policy initiatives through advisory and steering committee roles, including the UK National Institute for Health Research CONCORD Study Steering Committee and the Healthcare Regulation and Reimbursement Working Group of the University of London’s Future Targeted Healthcare Manufacturing Hub.

Sandra has been an active ISPOR member for 15 years, contributing to the Society through numerous scientific, leadership, and service roles. She currently serves as Program Committee Co-Chair for ISPOR Europe 2026 and on the Value & Outcomes Spotlight Editorial Advisory Board, including as section editor for the HTA Update column. Previously, she co-chaired the Rare Disease Special Interest Group, served on the ISPOR Task Force for Clinical Outcome Assessment in Rare Disease Clinical Trials, and participated regularly in the ISPOR Patient Representative Roundtable.

Sandra is passionate about solving complex challenges through collaborative, creative teamwork and uniting diverse stakeholders around a shared vision. She is also committed to mentoring and developing the next generation of HEOR leaders.

Sandra holds a PhD in Toxicology from the University of London, an MPhil in Biochemistry from the University of Cambridge, and an MSc in Health Economics, Policy and Management from the London School of Economics and Political Science.